XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants

Garyfallia Poulakou, Pierre-Joseph Royer, Nikolai Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez
doi: https://doi.org/10.1101/2023.10.09.23296726

Article usage

Article usage: October 2023 to May 2025

AbstractFullPdf
Oct 20234981873
Nov 202366442
Dec 202330111
Jan 20243947
Feb 20242446
Mar 20243851
Apr 20243667
May 20243355
Jun 20243366
Jul 202460513
Aug 20244078
Sep 202452194
Oct 202432107
Nov 202446114
Dec 202437124
Jan 20253962
Feb 202534184
Mar 2025463912
Apr 2025292412
May 20252033
Back to top
Posted October 19, 2023.
Download PDF
Data/Code
Email
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
Garyfallia Poulakou, Pierre-Joseph Royer, Nikolai Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez
medRxiv 2023.10.09.23296726; doi: https://doi.org/10.1101/2023.10.09.23296726
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area